Anticancer Therapies – Products

The trial is designed to demonstrate the overall survival benefit of IMA901 in combination with standard first-line therapy in RCC patients.

Trial could generate future alternative treatment for metastatic melanoma.

PharmaNet collaborate with CITN to help identify trials with immunotherapy agents prioritized by the CITN as having high potential for cancer therapy.

Eleven abstracts on nimotuzumab to be presented at ASCO.

Integrated capabilities offer deeper, broader understanding of proteomes and biological pathways.

Researchers in the US used a form of Benitec’s ddRNAi as a key component of their therapeutic molecule in preclinical studies both in vitro and in vivo.

Marks RPC's 3rd medical conference participation this year.

Network consists of 27 institutions with the goal of making effective immunotherapy agents broadly available for treatment of cancer.

Phase IIa study will investigate the optimal schedule for delivery of CYT107 and its ability to prevent or reverse the effects of chemotherapy-induced lymphopenia characterized by a low CD4 T cell count, identified as an independent prognostic factor for overall survival in patients with advanced cancers.

RTCA HT Instrument´s design allows for integration with automated plate and liquid handling systems.